Our combined analysis using genetic editing, RNA-seq, and proteomics enabled us to identify the pathway by which NLRC4 expression associates with enhanced DC profiles and T cell responses in cancer patients, controlling the evolution of the disease and improving the survival of patients. The gene discussed is NLRC4; the disease is cancer.